Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening (Oncotarget (2015) 6 (32868-32877) DOI: 10.18632/oncotarget.5210);Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

Oncotarget

Volumn 6, Issue 32, 2015, Pages 32868-32877

  Sestini, Stefano ^a   Boeri, Mattia ^a   Marchiano, Alfonso ^a   Pelosi, Giuseppe ^a,b   Galeone, Carlotta ^c   Verri, Carla ^a   Suatoni, Paola ^a   Sverzellati, Nicola ^d   Vecchia, Carlo La ^e   Sozzi, Gabriella ^a   Pastorino, Ugo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

LDCT screening; Liquid biopsy; Lung cancer; MicroRNA; Prognosis

Indexed keywords

MICRORNA; TUMOR MARKER;

ADULT; ARTICLE; BIOPSY TECHNIQUE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIQUID BIOPSY; LONGITUDINAL STUDY; LUNG CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICRORNA SIGNATURE RISK CLASSIFIER TEST; PATIENT MONITORING; RADIATION DOSE; RISK ASSESSMENT; SECOND CANCER; SENSITIVITY AND SPECIFICITY; ADVERSE EFFECTS; BIOPSY; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; EARLY CANCER DIAGNOSIS; EVALUATION STUDY; FEASIBILITY STUDY; GENE EXPRESSION PROFILING; GENETICS; ITALY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LUNG RESECTION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PILOT STUDY; PREDICTIVE VALUE; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

BIOMARKERS, TUMOR; BIOPSY; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIATION DOSAGE; RISK FACTORS; SMOKING; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84946014218     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5210     Document Type: Erratum

References (29)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.
2. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. The Lancet. Oncology. 2014; 15:23-34.
3. Crino L, Weder W, van Meerbeeck J, Felip E. ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2010; 21:v103-15.
4. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, Peters S. ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2013; 24:vi89-98.
5. National Lung Screening Trial Research Team Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine. 2011; 365:395-409.
6. Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, Chiles C, Black WC, Aberle DR. NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA internal medicine. 2014; 174:269-274.
7. van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, van Iersel CA, van den Bergh KA, van't Westeinde S, van der Aalst C, Thunnissen E, Xu DM, Wang Y, et al. Management of lung nodules detected by volume CT scanning. The New England journal of medicine. 2009; 361:2221-2229.
8. Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, Fabbri A, Galeone C, Negri E, Sozzi G, Pelosi G, La Vecchia C. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP). 2012; 21:308-315.
9. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, Dossing M, Hansen H, Kofoed KF, Larsen KR, Mortensen J, Rasmussen JF, Seersholm N, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012; 67:296-301.
10. Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. American journal of respiratory and critical care medicine. 2015; 191:1166-1175.
11. Bach PB. Perilous potential: the chance to save lives, or lose them, through low dose computed tomography screening for lung cancer. Journal of surgical oncology. 2013; 108:287-288.
12. Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer journal (Sudbury, Mass.). 2012; 18:215-222.
13. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:3713-3718.
14. Wu H, Haag D, Muley T, Warth A, Zapatka M, Toedt G, Pscherer A, Hahn M, Rieker RJ, Wachter DL, Meister M, Schnabel P, Muller-Decker K, et al. Tumormicroenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma. Genes, chromosomes & cancer. 2013; 52:250-264.
15. Wu R, Jiang Y, Wu Q, Li Q, Cheng D, Xu L, Zhang C, Zhang M, Ye L. Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014.
16. Mraz M, Malinova K, Mayer J, Pospisilova S. MicroRNA isolation and stability in stored RNA samples. Biochemical and biophysical research communications. 2009; 390:1-4.
17. Boeri M, Sestini S, Fortunato O, Verri C, Suatoni P, Pastorino U, Sozzi G. Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. Expert review of molecular diagnostics. 2015; 15:801-813.
18. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, Marchiano A, Negri E, La Vecchia C, et al. Clinical utility of a plasmabased miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32:768-773.
19. Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, Pelosi G, Boyle P, Fazio F. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003; 362:593-597.
20. Fortunato O, Boeri M, Verri C, Conte D, Mensah M, Suatoni P, Pastorino U, Sozzi G. Assessment of circulating microRNAs in plasma of lung cancer patients. Molecules (Basel, Switzerland). 2014; 19:3038-3054.
21. EL, Kaplan PM. Nonparametric Estimation from Incomplete Observations. 1958; 53:457-481.
22. Boeri M, Pastorino U, Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer journal (Sudbury, Mass.). 2012; 18:268-274.
23. Li J, Yang S, Yan W, Yang J, Qin YJ, Lin XL, Xie RY, Wang SC, Jin W, Gao F, Shi JW, Zhao WT, Jia JS, et al. MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Laboratory investigation; a journal of technical methods and pathology. 2015.
24. Li Y, Shi Y, McCaw L, Li YJ, Zhu F, Gorczynski R, Duncan GS, Yang B, Ben-David Y, Spaner DE. Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A. Blood. 2015.
25. Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M, De Maria R. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell death and differentiation. 2014; 21:774-782.
26. Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D, Caleca L, Roz L, Pastorino U, Sozzi G. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell death & disease. 2014; 5:e1564.
27. Peng Y, Dai Y, Hitchcock C, Yang X, Kassis ES, Liu L, Luo Z, Sun HL, Cui R, Wei H, Kim T, Lee TJ, Jeon YJ, et al. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:15043-15048.
28. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M, Van Brocklyn J, Ostrowski MC, Chiocca EA, Lawler SE. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Molecular cell. 2010; 37:620-632.
29. Chen D, Goswami CP, Burnett RM, Anjanappa M, BhatNakshatri P, Muller W, Nakshatri H. Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle. Cancer research. 2014; 74:4270-4281.